Form 8-K - Current report:
SEC Accession No. 0001193125-26-336886
Filing Date
2026-08-06
Accepted
2026-08-06 08:30:16
Documents
13
Period of Report
2026-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ck0001991792-20260806.htm   iXBRL 8-K 57955
2 EX-5.1 ck0001991792-ex5_1.htm EX-5.1 26553
3 EX-99.1 ck0001991792-ex99_1.htm EX-99.1 178054
4 GRAPHIC img89521117_0.jpg GRAPHIC 36479
5 GRAPHIC img234575362_0.jpg GRAPHIC 90263
  Complete submission text file 0001193125-26-336886.txt   564245

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001991792-20260806.xsd EX-101.SCH 26013
16 EXTRACTED XBRL INSTANCE DOCUMENT ck0001991792-20260806_htm.xml XML 4933
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1640 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1640 DALLAS TX 75247 (949) 409-3700
CG Oncology, Inc. (Filer) CIK: 0001991792 (see all company filings)

EIN.: 371611499 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41925 | Film No.: 261246229
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)